Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN9101 in Relapsed/Refractory Multiple Myeloma
NCT07628595Phase 1Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RN9101 in multiple myeloma (MM), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Dose-limiting toxicities up to 28 days, Cytokine release syndrome up to 28 days and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
RN9101
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07628595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07628595.